[go: up one dir, main page]

AU2001261737A1 - Methods and compositions for promoting angiogenesis using monocytes - Google Patents

Methods and compositions for promoting angiogenesis using monocytes

Info

Publication number
AU2001261737A1
AU2001261737A1 AU2001261737A AU6173701A AU2001261737A1 AU 2001261737 A1 AU2001261737 A1 AU 2001261737A1 AU 2001261737 A AU2001261737 A AU 2001261737A AU 6173701 A AU6173701 A AU 6173701A AU 2001261737 A1 AU2001261737 A1 AU 2001261737A1
Authority
AU
Australia
Prior art keywords
monocytes
compositions
methods
promoting angiogenesis
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261737A
Inventor
Philippe Leboulch
Robert Pawliuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Genetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc filed Critical Genetix Pharmaceuticals Inc
Publication of AU2001261737A1 publication Critical patent/AU2001261737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001261737A 2000-05-18 2001-05-18 Methods and compositions for promoting angiogenesis using monocytes Abandoned AU2001261737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20506300P 2000-05-18 2000-05-18
US60205063 2000-05-18
PCT/US2001/016026 WO2001087314A1 (en) 2000-05-18 2001-05-18 Methods and compositions for promoting angiogenesis using monocytes

Publications (1)

Publication Number Publication Date
AU2001261737A1 true AU2001261737A1 (en) 2001-11-26

Family

ID=22760628

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261737A Abandoned AU2001261737A1 (en) 2000-05-18 2001-05-18 Methods and compositions for promoting angiogenesis using monocytes

Country Status (3)

Country Link
US (1) US20020034501A1 (en)
AU (1) AU2001261737A1 (en)
WO (1) WO2001087314A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
KR20030093316A (en) * 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP2007217283A (en) * 2004-03-30 2007-08-30 Niigata Tlo:Kk Angiogenesis promoters and angiogenesis therapy
US20070293893A1 (en) * 2006-06-14 2007-12-20 Craig Stolen Method and apparatus for preconditioning of cells
WO2010031006A1 (en) * 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
WO2010060104A2 (en) * 2008-11-24 2010-05-27 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension
WO2011065968A1 (en) * 2009-11-30 2011-06-03 The Scripps Research Institute Use of monocyte chemoattractant compounds to treat ocular disorders
WO2012018930A1 (en) * 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
WO2013062489A1 (en) * 2011-10-28 2013-05-02 National University Of Singapore Lymphatic vessel endothelial hyaluronic acid receptor-1 (lyve-1+) macrophages and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (en) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Cellular compositions, preparation and therapeutic uses.
WO1998044953A1 (en) * 1997-04-04 1998-10-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
DK1019082T4 (en) * 1997-10-02 2008-10-27 Max Planck Gesellschaft Method for modulating neovascularization and / or growth of collateral arteries and / or other arteries from pre-existing arteriolar connections
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof

Also Published As

Publication number Publication date
US20020034501A1 (en) 2002-03-21
WO2001087314A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2778801A (en) Antisense compositions and methods
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001286233A1 (en) Cement composition
AU2002221934A1 (en) Health promoting compositions
AU2705201A (en) Ceramic structure
AU2001248742A1 (en) Compositions for promoting sleep
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2001292864A1 (en) Methods and compositions for modulating angiogenesis
AU2001249855A1 (en) Aqueous mineral compositions and methods for their use
ZA200302014B (en) Methods and compositions for promoting the maturation of monocytes.
AU2001261737A1 (en) Methods and compositions for promoting angiogenesis using monocytes
AU2001240018A1 (en) Adeno-associated viral compositions and methods
AU2001241098A1 (en) Composition
AU2001233932A1 (en) Method and composition
AU2001262090A1 (en) Solid dispersible abrasive compositions
AU2001275201A1 (en) Acne-treating composition
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2001247447A1 (en) Mocvd-grown emode higfet buffer
AU2001271801A1 (en) Compositions and methods for producing recombinant virions
AU2001235764A1 (en) Compositions
AU2001287852A1 (en) Composition
AU2001267541A1 (en) Vaccine composition
AU1182402A (en) Methods and compositions for enhancing angiogenesis
AU2002239775A1 (en) Chemical-library composition and method
AU2001287732A1 (en) Copolycarbonate-based composition